



HEIDELBERG
UNIVERSITY
HOSPITAL

dkfz.

GERMAN
CANCER RESEARCH CENTER
IN THE HELMHOLTZ ASSOCIATION




Research for a Life without Cancer

PANHPVAX study – vaccination against human papillomaviruses

Healthy volunteers wanted

The clinical phase I study is assessing the safety, tolerability and immunogenicity of a novel vaccine (PANHPVAX antigen with cyclic di-AMP as booster) against human papillomaviruses in healthy volunteers.

Study period	7 to 8 months
Time commitment	15 visits at the study center: 3 x all day for vaccination, approx. 8 hrs each 1 x screening and 1 x follow-up, approx. 1.5 hrs each 10 x check-ups, approx. 30 min. each <i>Times indicated are approximate. The study days will be planned flexibly.</i>
Study procedure	Total of three vaccinations with the novel vaccine PANHPVAX Control checks (blood samples, physical examinations)
Participants	Healthy men and women
Age	18 to 45 years
Requirements	No regular use of medication (except for oral contraceptives/ "the pill", thyroid hormones) Reliable contraception methods used Not yet vaccinated against human papillomaviruses (HPV) No known chronic HPV infection (e.g. chronic genital warts)
Compensation	EUR 2,000
Principal investigator/ lead physician	PD Dr. med. Antje Blank Heidelberg University Hospital Medical Clinic Dept. of Clinical Pharmacology and Pharmacoepidemiology Early Clinical Trial Unit Pharmacology (KliPS) Im Neuenheimer Feld 410 69120 Heidelberg



Are you interested? Then call in for a face-to-face chat!

To arrange an appointment, please contact the Early Clinical Trial Unit Pharmacology (KliPS) of Heidelberg University Hospital:

Phone: 06221 56-38745 | email: klips@med.uni-heidelberg.de



PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de

PANHPVAX study

Early Clinical Trial Unit Pharmacology
(KliPS)
Phone: 06221 56-38745
email: klips@med.uni-heidelberg.de